To assess the effects of JNK1/2 on NEU tumor cells, we treated NEU PKR+/+ and PKR−/− tumor cells with the JNK1/2 inhibitor SP600125 in the range of the half-maximal inhibitory concentration (IC50 ~50 nM)24. This evidence concerns the gene MAPK8 and neoplasm.